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Abstract
Background: Multimorbidity, the presence of two or more chronic conditions, affects over 60 % of patients in
primary care. Due to its association with polypharmacy, the development of interventions to optimise medication
management in patients with multimorbidity is a priority. The Behaviour Change Wheel is a new approach for
applying behavioural theory to intervention development. Here, we describe how we have used results from a
review of previous research, original research of our own and the Behaviour Change Wheel to develop an
intervention to improve medication management in multimorbidity by general practitioners (GPs), within the
overarching UK Medical Research Council guidance on complex interventions.
Methods: Following the steps of the Behaviour Change Wheel, we sought behaviours associated with medication
management in multimorbidity by conducting a systematic review and qualitative study with GPs. From the
modifiable GP behaviours identified, we selected one and conducted a focused behavioural analysis to explain why
GPs were or were not engaging in this behaviour. We used the behavioural analysis to determine the intervention
functions, behavioural change techniques and implementation plan most likely to effect behavioural change.
Results: We identified numerous modifiable GP behaviours in the systematic review and qualitative study, from which
active medication review (rather than passive maintaining the status quo) was chosen as the target behaviour.
Behavioural analysis revealed GPs’ capabilities, opportunities and motivations relating to active medication review. We
combined the three intervention functions deemed most likely to effect behavioural change (enablement, environmental
restructuring and incentivisation) to form the MultimorbiditY COllaborative Medication Review And DEcision Making (MY
COMRADE) intervention. MY COMRADE primarily involves the technique of social support: two GPs review the
medications prescribed to a complex multimorbid patient together. Four other behavioural change techniques are
incorporated: restructuring the social environment, prompts/cues, action planning and self-incentives.
Conclusions: This study is the first to use the Behaviour Change Wheel to develop an intervention targeting
multimorbidity and confirms the usability and usefulness of the approach in a complex area of clinical care. The
systematic development of the MY COMRADE intervention will facilitate a thorough evaluation of its effectiveness in
the next phase of this work.
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Background
Multimorbidity, the presence of two or more chronic
conditions, affects over 60 % of patients in primary care
[1]. In a healthcare system that has evolved around the
management of single chronic diseases, this presents
major challenges to healthcare provision, research and
medical education [2]. In 2014, the US Department of
Health and Human Services recognised these challenges
by stating the need to better equip clinicians in the man-
agement of multimorbidity, making specific reference to
medication management [3]. Multimorbidity frequently
leads to the prescription of multiple long-term medica-
tions [4]. The resulting polypharmacy is an independent
risk factor for negative health outcomes such as adverse
effects and drug interactions [5]. For prescribers, this
creates a tension between keeping the number of medi-
cines to a minimum while still prescribing what
evidence-based guidelines advocate as being in the pa-
tient’s best interest [6]. This is especially the case for
general practitioners (GPs), who must coordinate and
oversee the medications prescribed by numerous doctors
involved in the care of a multimorbid patient [7].
Despite the prevalence of multimorbidity, few inter-
ventions have been developed to improve medication
management in this field to date. A recent systematic re-
view, which focussed on interventions to optimise out-
comes in patients with multimorbidity in primary care,
found only two that specifically addressed medication
management. However, both interventions related to en-
hanced involvement of pharmacists, rather than the pre-
scribing actions of GPs [8]. Thus, the development of
interventions to improve GPs’ contribution to medi-
cation management in patients with multimorbidity
is a priority.
In the past, interventions that aimed to change health-
care professionals’ behaviour have resulted in suboptimal
effects, due to a lack of theoretical consideration at the
development stage [9]. The UK Medical Research Coun-
cil (MRC) guidance for the development of complex in-
terventions in healthcare emphasises the importance of
using theory in intervention design [10]. However, the
MRC document does not put forth any specific sugges-
tions on how to do this which leaves intervention de-
signers, many of whom are interested in theory only to
the extent that it can help them achieve improvements
in clinical care, with an array of dilemmas [11]. The
large pool of available theoretical models means that
critical theories may be missed, and there is little clarity
on how to choose the most appropriate theory for the
behaviour in question [12]. In addition, intervention de-
velopers have traditionally had little to guide them on
the specification of intervention content [13].
Over the last few years, this gap has been addressed by
an approach known as the Behaviour Change Wheel
(BCW), which explicitly integrates behavioural theory
with the development and description of behavioural
change interventions [14]. A core feature of the BCW is
a theoretical model which is used to conduct an analysis
of the behaviour in question. The model is based on the
hypothesis that the interaction between one’s capability
(C), opportunity (O) and motivation (M) can provide ex-
planations for why a particular behaviour (B) is or is not
performed (COM-B). Each of these components can be
further subdivided (Fig. 1). Capability may be physical
(the physical skill, strength and stamina) or psycho-
logical (the knowledge or psychological skills, strength
or stamina to engage in the necessary mental processes).
Opportunity may be physical (afforded by the environ-
ment, including resources, locations, time etc.) or social
(afforded by interpersonal influences, social cues, and
cultural norms that influence the way we think about
things). Motivation may be reflective (plans, self-
conscious intentions or evaluations) or automatic (reflex
responses, impulses, drive states). The COM-B behav-
ioural analysis guides the choice of intervention func-
tions (or strategies) most likely to achieve behavioural
change. Additionally, the intervention functions have
been linked to a taxonomy of 93 replicable behavioural
change techniques [15], and those techniques particu-
larly suitable for each intervention function have been
highlighted [14]. Following this structured approach
lends transparency to the process of intervention devel-
opment and facilitates its subsequent implementation
and evaluation [12].
Since its original publication in 2011, the BCW has re-
ceived a lot of academic interest, and a number of
groups have already used it to develop or study the im-
plementation of interventions by healthcare profes-
sionals [16–19]. To our knowledge, there are no
published examples of using the BCW to develop a de
novo intervention targeted at healthcare professionals in
the complex field of multimorbidity. As the application
of the BCW may vary according to the setting and target
behaviour, examples of the generalizability of the ap-
proach are required. Furthermore, published examples
of its use will contribute to the ongoing development
and refinement of the method.
In this paper, we describe the development of an inter-
vention to improve medication management in multi-
morbidity by GPs, in which we applied the steps of the
BCW to enable a more transparent implementation of
the MRC framework for design and evaluation of com-
plex interventions.
Methods
In the MRC framework, intervention development com-
prises three stages: identifying the evidence base, identi-
fying and applying appropriate theory to the available
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(and if necessary, new) evidence and modelling process
and outcomes [10]. Like the MRC framework, the BCW
[14] also has three broad stages but they involve differ-
ent tasks (i.e. understanding the behaviour, identifying
intervention options and identifying content and imple-
mentation options) and are subdivided into a further
eight steps (i.e. defining the problem in behavioural
terms, selecting the target behaviour, specifying the tar-
get behaviour, identifying what needs to change, identify
appropriate intervention functions, identifying policy
categories, identifying behavioural change techniques
and determining the mode of delivery) [14]. As we were
using the BCW within the overarching framework of the
MRC, we mapped the eight BCW steps directly on to
the three development stages of the MRC to en-
hance the clarity and generalizability of our approach
(see Table 1).
MRC stage 1: identifying the evidence base
To begin, we reviewed the existing evidence on medica-
tion management in multimorbidity and supplemented
this with new evidence in order to clearly define our
problem of interest and then select and specify the be-
havioural target for intervention.
BCW step 1: define the problem in behavioural terms
We searched for relevant published literature, in particu-
lar existing systematic reviews, to help us understand
the problems associated with medication management in
multimorbidity in primary care. While we identified two
relevant quantitative reviews [8, 20], we also found a
number of pertinent qualitative studies. Therefore, we
conducted a systematic review and synthesis of the rele-
vant qualitative evidence, the methods of which have
been published elsewhere [21].
Fig. 1 The Behaviour Change Wheel
Table 1 Mapping steps of Behaviour Change Wheel to the three stages of intervention development in the UK Medical Research
Council guide on complex interventions in healthcare
MRC development stage [10] BCW steps [14] BCW stages
1. Identify the evidence base 1. Define the problem in behavioural terms 1. Understand the behaviour
2. Select the target behaviour
3. Specify the target behaviour
2. Identify/develop theory 4. Identify what needs to change
5. Identify appropriate intervention functions 2. Identify intervention options
6. Identifying policy categories
3. Model process and outcomes 7. Identifying behavioural change techniques 3. Identify content and implementation options
8. Determine the mode of delivery
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We addressed the gaps identified from the qualitative
synthesis by conducting a qualitative interview study
with GPs, specifically to generate further information on
their approaches to prescribing in multimorbidity. The
methods for the interview study have also been pub-
lished elsewhere [22].
BCW step 2: select the target behaviour
From the aggregated qualitative synthesis and interview
data, we (CS and CB) identified the modifiable GP be-
haviours relating to medication management in multi-
morbidity and selected one key behaviour to target in
our intervention. This judgement was informed by cri-
teria set out in the BCW guide which are the likelihood
that behavioural change would be implemented, the
likely impact of changing the behaviour, the spillover or
knock on effect of change on other behaviours and the
ease with which each behaviour could be measured [14].
BCW step 3: specify the target behaviour
Once the target behaviour was decided, we specified in
greater detail what and who needs to change and where
and when this change should happen.
MRC stage 2: identifying/developing theory
In the next stage, we used the COM-B (capability, op-
portunity, motivation—behaviour) model to develop a
theoretical understanding of the target behaviour and
guide our choice of intervention functions.
BCW step 4: identify what needs to change to achieve the
desired behaviour
We used the COM-B model to frame our qualitative be-
havioural analysis of the qualitative synthesis and inter-
view data. We (CS and CB) coded empirical data
relevant to GPs’ psychological and physical capabilities
(C), social and physical opportunities (O) and reflective
and automatic motivations (M) to highlight why GPs
were or were not engaging in the target behaviour and
what needed to change for the target behaviour to be
achieved. Where multiple COM-B components were po-
tentially relevant to one section of the data, the compo-
nent whose definition (as set out in the BCW guide,
[14]) best fit the context of our data was chosen. The re-
sults of this analysis was presented to the other authors
at a consensus meeting and refined accordingly.
BCW step 5: identify intervention functions to achieve the
desired behaviour
The BCW incorporates a comprehensive panel of nine
intervention functions, shown in Fig. 1, which were
drawn from a synthesis of 19 frameworks of
behavioural-intervention strategies. We determined
which intervention functions would be most likely to
effect behavioural change in our intervention by map-
ping the individual components of the COM-B behav-
ioural analysis onto the published BCW linkage matrices
[14]. Each intervention function seen to be potentially
relevant to our data was considered in detail. We used
the affordability, practicability, effectiveness and cost-
effectiveness, acceptability, side effects/safety and equity
(APEASE) criteria, another component of the BCW ap-
proach, to grade the potentially relevant intervention
functions into first and second line options [14].
BCW step 6: policy categories
The BCW also includes matrices which signpost the
seven broad policy-level interventions for achieving be-
havioural change, shown in Fig. 1. As we were not pri-
marily concerned with changing policy in this study, we
did not undertake this step in detail, other than listing
the options that may be relevant to levering our inter-
vention in the future.
MRC stage 3: modelling process and outcomes
In this third stage, we specified our intervention content
in more detail and identified an appropriate way of
implementing the intervention within our context.
BCW step 7: identify behavioural change techniques
The selected intervention functions represented our
broad approach to achieving behavioural change, but we
required fine-grained techniques to operationalise these
functions. We used the links previously drawn between
the BCW and the taxonomy of 93 behavioural change
techniques [14, 23] to list those techniques most fre-
quently used with our selected intervention functions.
We held an expert panel consensus meeting to review
the suitability of each of these techniques, in the light of
our previously collected qualitative data, the context of
the intervention and by referring to the APEASE criteria.
Each member of the panel had expertise in one or more
areas of relevance (clinical pharmacology and prescrib-
ing (CB, MD, RP), general practice (CB, CS, MD, RP,
SM), behavioural science and intervention design (MB)
and multimorbidity (CS, RP, SM)).
BCW step 8: identify mode of delivery
As we were developing an intervention to be imple-
mented by individual GPs, this step (mode of delivery)
required explicit consideration of implementation in the
heterogeneous setting of general practice. We used the
expert panel consensus to specifically address modelling
questions posed in the MRC framework which were
would it be possible to use this, what subgroup of pa-
tients should it be used for, what outcomes should be
sought and what are the facilitators/obstacles at practice
level [10]. If multiple implementation options existed,
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agreement was reached by discussing each option, with
reference to the APEASE criteria [14].
Results
MRC stage 1: identifying the evidence base
BCW step 1: define the problem in behavioural terms
We identified two existing systematic reviews which
were relevant. Patterson et al. reviewed existing inter-
ventions to improve prescribing and polypharmacy in
older patients [20]. Only one of the included studies in-
volved GPs and showed that computer decision support
reduced inappropriate drug initiation in primary care
[24]. The authors suggested that future polypharmacy
interventions must address the complexity of clinical sit-
uations and the individuality of prescribers. Smith et al.
reviewed interventions to improve patient outcomes in
multimorbidity in primary care. Two included studies
addressed medication management but these involved
pharmacists rather than GPs. Here, the authors sug-
gested that future interventions should target specific
problems relating to multimorbidity, be integrated into
existing healthcare systems and be embedded with inter-
professional collaboration [8].
Our qualitative synthesis included ten studies from
seven countries involving a total of 275 GPs [21]. A key
theme was GPs’ sense of professional isolation in the
management of multimorbid patients. This emanated
from the interplay between four aspects of the manage-
ment of patients with multimorbidity: (i) the disorgan-
isation and fragmentation of healthcare between primary
and secondary care, (ii) the inadequacy of guidelines and
evidence-based medicine for multimorbidity, (iii) chal-
lenges in delivering patient-centred, rather than
disease-focused, care and (iv) barriers to shared
decision-making.
In the qualitative interview study, we interviewed 20
GPs about 51 multimorbid cases [22]. We found that
GPs responded to clinical dilemmas in multimorbidity
by ‘satisficing’, i.e. accepting care that they deemed satis-
factory and sufficient for a particular patient, yet ac-
knowledging that aspects of that care may not be
optimal. In patients with changing disease trajectories,
satisficing was manifested as relaxing targets for disease
control, negotiating compromise with the patient, or
making ‘best guesses’ about the most appropriate course
of action to take. In multimorbid patients perceived as
stable, GPs’ default approach was to ‘maintain the status
quo’ rather than actively rationalise medications.
BCW step 2: select the target behaviour
The numerous modifiable GP behaviours relating to
medication management in multimorbidity are shown in
Fig. 2. ‘Maintaining the status quo’ was observed in all of
the qualitative interviews despite best practice guidelines
which state that patients receiving long-term medicines
need medication reviews at regular intervals. Targeting
this behaviour would likely result in behavioural change
as the qualitative study showed GPs extant discomfort
with it [22]. Furthermore, it would be desirable to see
GPs adopt a less-passive approach to medication man-
agement even if it did not always lead to downstream
changes to medications. There was a high possibility of
‘spill over’ of the actions of medication review for multi-
morbidity into other prescribing activities. Lastly, chan-
ging this behaviour would be relatively easy to measure.
We judged that the other modifiable behaviours were
not as attractive: adopting practice protocols would have
a big impact and high spillover, but given current finan-
cial and staffing pressure on practices would be a diffi-
cult organisational change to achieve; relaxing targets
and negotiating compromise may be argued to be appro-
priately patient-centred in multimorbidity and trying to
change these, in a healthcare system where progressively
less appears to be patient-centred, may be resisted by
GPs; addressing shared decision-making has merit but
requires interventions targeting GPs’ communication
skills (rather than prescribing) which was not our spe-
cific focus.
BCW step 3: specify the target behaviour
The target behaviour was specified as active, purpose-
ful medication review instead of passive ‘maintaining
the status quo’ for patients with multimorbidity, to be
conducted by GPs, in routine general practice, on a
regular basis.
Fig. 2 Modifiable GP behaviours in medication management in
multimorbidity identified in qualitative synthesis [21] and interview
study [22]
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MRC stage 2: identifying/developing theory
BCW step 4: identify what needs to change to achieve the
desired behaviour
We used COM-B to identify GPs’ capabilities (C), oppor-
tunities (O) and motivations (M) for engaging, or not
engaging, in active medication review. The themes that
emerged from this analysis are shown in Table 2, with il-
lustrative quotes from the qualitative synthesis and the
interview study. For example, GPs adopted a passive ap-
proach to medication management due to their uncer-
tainty (lack of psychological capability) about which
medications were most valuable in patients with multi-
morbidity, especially given the absence of satisfactory
guidelines in this field. Insufficient time within the con-
sultation led to a lack of physical opportunity to review
medications. GPs also found medication review difficult
because of a cultural milieu which holds that treatment
for chronic disease is lifelong (lack of social opportun-
ity). This was especially the case if the patient had been
compliant with their medications for many years. Many
GPs had developed a habitual response to ‘not rock the
boat’ in patients with multimorbidity, an approach which
involved not making changes to medications unless
there was a pressing reason to do so. This response was
reinforced by their experiences of the negative conse-
quences of stopping or changing medications for pa-
tients with multimorbidity in the past (automatic
motivation). GPs’ reflective motivations against medica-
tion review included the opportunity cost of using their
professional time for this purpose and a fear of negative
consequences from rationalising medications. GPs also
had motivations to review medications which included
improving patient outcomes, reassuring themselves that
they are delivering best care, and guarding against
medico-legal repercussions.
BCW step 5: identify intervention functions
We found that all nine intervention functions listed in
the BCW were relevant to our behavioural analysis.
Additional file 1 shows our assessment and grading of
each intervention function using the APEASE criteria
into first and second line options. The three intervention
functions most relevant for our intervention were en-
ablement, environmental re-structuring and incentivisa-
tion. The relationship between the components of the
COM-B behavioural analysis and the three selected
intervention functions are shown in Table 2.
BCW step 6: policy categories
The broad policy options, signposted by the BCW matri-
ces as being potentially useful for achieving behavioural
change, were communication/marketing, service provision
policy, legislation, guidelines and regulation.
MRC stage 3: modelling process and outcomes
BCW step 7: identify behavioural change techniques
From the taxonomy of 93 behavioural change tech-
niques, we listed the techniques most frequently
used to deliver the three intervention functions we
had selected [14, 23]. The resulting 32 potentially
relevant techniques are listed in Additional file 2. In
the expert panel, we reviewed how each technique
could be applied to the context of medication man-
agement in multimorbidity. The panel’s choice of
techniques was influenced principally by the key
findings of the qualitative studies: GPs’ sense of iso-
lation in the management of multimorbid patients
revealed in the qualitative synthesis [21], and GPs’
lack of certainty and efforts to ‘share the onus of re-
sponsibility’ seen in the interview study [22]. Thus,
we focused on options that would enhance GPs’
means of professional support. Although enhanced
communication between GPs and pharmacists is be-
ing investigated in other healthcare systems [25, 26],
it is not currently an option in Irish general practice
due to the lack of community pharmacists. Similarly,
communication between GPs and the specialists in-
volved in multimorbidity patient care was seen in
both qualitative studies to be fraught with poor ac-
cess and a single-disease approach. A useful source
of support for some GPs in the interview study was
their GP colleagues. These interactions occurred on
an informal basis within practices and were notable
for their ready accessibility and generalist nature
[22]. We were unaware of any work exploring col-
laborative decision-making between GPs in multi-
morbidity, so focused on this approach. From the
list of 32, we considered which techniques would
pragmatically facilitate collaborative decision-making
between GPs. Additional file 2 shows how many
were quickly eliminated as not being relevant to the
context or purpose of the intervention. The five
techniques eventually selected as ‘active ingredients’
were social support (practical), restructuring the so-
cial environment, use of prompts/cues, action plan-
ning and self-incentives. The definition of each
technique and qualitative data to support their selec-
tion are shown in Table 2. The combination and inte-
gration of each technique into the overall intervention,
named MultimorbiditY COllaborative Medication Re-
view And DEcision Making (MY COMRADE), is
shown in Table 3.
BCW step 8: identify mode of delivery
In the expert panel meeting, we then formulated an
intervention implementation plan. Four specific as-
pects of implementation were reviewed, and the vari-
ous options considered for each aspect are fully
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Table 2 Behavioural analysis, selected intervention functions and behavioural change techniques, referencing empirical data from
the qualitative synthesis (QS) and the interview study (IS)
Sinnott et al. Implementation Science  (2015) 10:132 Page 7 of 11
described in Additional file 3. In summary, the fol-
lowing implementation plan was formulated:
1. What prompts should be used to guide medication
review in MY COMRADE?
After reviewing eight different prescribing tools and
checklists (listed in Additional file 3), it was agreed
that a modified version of the seven prompts in the
NOTEARS [27] checklist for medication review
would be used to cue the review.
2. How should GPs choose which patients to review
using MY COMRADE?
After reviewing multiple options (see Additional file
3), it was agreed that GPs should choose patients
prescribed ten or more regular medicines or four or
more medicines with at least one other complicating
factor (i.e. meets criteria for potentially
inappropriate prescribing, at risk of a well-
recognised drug-drug interaction, has poor adher-
ence or receiving end-of-life or palliative care), in
line with recommendations from the Kings Fund re-
port on Polypharmacy and Medication Optimisation
[28].
3. How should the behavioural change technique
“action planning” be operationalised?
One of the behavioural change techniques, action
planning, specifically relates to implementation and
was selected to account for the wide variety of
structures and systems that occur in general
practice. Each GP will be given clear guidance on
how to tailor MY COMRADE to suit their practice.
This will involve asking them to choose a particular
day, time of the day and office in which to do the
review. They will decide on the number of cases to
review in one sitting, and the GP pairs that will
conduct reviews within a practice. In advance of
trialling MY COMRADE, GPs will be asked to
consider what they envision as problematic for its
implementation, and how these problems could be
tackled, knowing their own practice.
4. How should the intervention be evaluated?
The initial evaluation will focus on intervention
implementation (i.e. did medication review take
place?). The behavioural change techniques and
other causal or contextual mechanisms associated
with behavioural change will be determined using
qualitative methods. If MY COMRADE is shown to
be effective, future evaluations will assess other
health outcomes such as the number of/type of
medication changes made and changes in rates of
healthcare utilisation.
Discussion
This paper describes the systematic, structured develop-
ment of an intervention to improve medication manage-
ment for multimorbid patients by GPs. The intervention
is called MY COMRADE. It is, to our knowledge, the
first intervention directed at the management of multi-
morbidity in primary care, developed by using the Be-
haviour Change Wheel to clearly implement the
framework of the MRC guide on complex interventions.
MY COMRADE involves collaborative decision-
making by two GPs who support each other in the
review of medications prescribed to a complex multi-
morbid patient, guided by cues which relate to safe
prescribing. The broad functions of the intervention
(enablement, environmental restructuring and incenti-
visation) are theoretically based. These functions will
be achieved using five specific behavioural change
techniques: social support (practical), restructuring
the social environment, use of prompts/cues, action
planning and self-incentives. The technique of colle-
gial social support is a crucial feature of our interven-
tion, which we expect will greatly enable GPs’
capabilities in conducting active medication reviews.
It may be particularly important in de-prescribing
medications or prioritising patient-centred rather than
disease-focused care in multimorbidity which are
challenging aspects of medication management, not
least because of the fear of litigation which this inter-
vention may now help ameliorate.
Comparison with other work
Since its publication in 2011, the BCW has been used in
the development of interventions targeting healthcare pro-
fessionals in a variety of ways. For example, Alexander et
al. used COM-B to understand barriers and enablers to
preventative health examinations for young children in
Australian general practice, with a view to designing an
Table 3 Description of final intervention
The final intervention is called MultimorbiditY COllaborative Medication
Review And DEcision Making (MY COMRADE)
It involves the following (relevant behavioural change techniques are in
brackets):
GPs will be asked to schedule protected time for themselves and one of
their GP colleagues to conduct the collaborative medication review and
enter this time into the practice appointment book. They will be asked
to choose a day/time/office that suits them best and decide how many
patient cases to review in one sitting (action planning). The GPs will
choose multimorbid patients from their caseload and in the scheduled
review time will review medications, supported by their GP colleague
(social support and restructuring social environment). The medication
review will be cued by the seven prompts described in the NO TEARS
[27] medication checklist (prompts and cues). GPs will be asked to
record recommendations for medication change that arise from the
review in the patient’s notes to allow them to discuss these with the
patient during their next consultation. After completing the review, GPs
will award themselves continuing professional development points: one
point for each cumulative hour of the activity completed (self-incentives).
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implementation intervention to increase the conduct of
these examinations [16]. They did not describe later steps
of the BCW, such as choice of intervention functions, and
did not describe in detail how their implementation inter-
vention would look. In contrast, we used the BCW to
highlight areas for improvement in professional practice
and then develop an intervention targeted to these areas,
rather than simply increasing the implementation of a
pre-existing intervention.
Murphy et al. used COM-B to develop a capacity-
building programme to enhance pharmacists’ roles in
mental health care [19]. This group felt that implemen-
tation processes must be prioritised during the early
stages of intervention development, and they wove theor-
ies of behavioural change and implementation together in
an iterative way. While we agree that implementation
should be considered at all stages of development work,
we did not find it necessary to use a specific implementa-
tion framework. The initial steps of the BCW revealed
multiple areas for improvement in GPs’ professional prac-
tice. Once one had been chosen, the remaining steps of
the BCW involved developing an implementation inter-
vention to enhance the performance of this desired behav-
iour. Additionally, by incorporating the behaviour change
technique of action planning, implementation was expli-
citly integrated into our intervention. Action planning re-
quires an individual GP to plan the frequency, duration
and intensity of the planned intervention activity [14].
Thus, rather than a prescriptive implementation strategy,
action planning will allow each GP to adapt the interven-
tion for use within their own practice. The variation in im-
plementation, as well as fidelity to other behavioural
change techniques, will be evaluated in the next phase of
this work and will help to inform the debate on optimal
approaches to implementation planning in intervention
development.
Strengths and weaknesses
We began this work with the broad aim of developing
an intervention to improve medication management
in multimorbidty, but we did not have a predefined
idea of what the intervention would be at the outset.
Adhering to the guidance of the MRC by using a the-
oretical approach, which was chosen a priori, lent dir-
ection, structure and transparency to this process in
multiple ways.
First, the MRC states the need to identify the evi-
dence base and supplement this with new evidence if
necessary. In doing this, we generated much needed
data on the management of medications in multimor-
bidity, increased our understanding of the problematic
areas experienced by GPs and revealed how they cur-
rently respond to these difficulties. Second, we then
used this empirical data to directly influence the de-
velopment of the intervention. Following the steps of
the BCW allowed us to develop a list of options for
behavioural change and to clarify what we were, and
what we were not, trying to achieve. Third, we bene-
fitted from using the links between the BCW model
and the taxonomy of behavioural change techniques.
The taxonomy highlighted novel strategies for behav-
ioural change, many of which we would heretofore
not have considered. Although only five techniques
are ultimately included in the description of the final
intervention, many of the others influenced other as-
pects of intervention development and the implemen-
tation strategy.
Despite the highly systematic and structured approach
of the BCW, there are challenges associated with its use
and it is not a magic bullet for intervention develop-
ment. For example, the researcher must make a series of
subjective and pragmatic decisions throughout the
process. These ‘real life’ decisions can seem at odds with
the scientific approach. To counter this and to improve
the transparency and generalizability of our methods, we
recorded in detail the multiple options available to us at
each step of the BCW and expanded on why options
were or were not taken.
Furthermore, the multiple steps of intervention devel-
opment involved a lengthy process: from the beginning
of our systematic review to the final refinements of the
intervention spanned almost 3 years. Such a prolonged
course must be factored in by those pursuing and fund-
ing evidence-based intervention development. Other
intervention developers have used a ‘top-down’ approach
of applying classical behavioural theories such as social
cognitive [29] or control theory [30] to inform their
choice of intervention functions and behavioural change
techniques. In contrast, we employed a ‘bottom-up’ ap-
proach to theory development in which the framework
of the BCW guided our use of existing evidence and
our own qualitative explorations. This led to an
intervention which was logical and practical yet still
theoretically based.
In addition to the COM-B, the BCW also includes an
optional, more detailed framework for behavioural analysis
known as the Theoretical Domains Framework [14]. After
completing our intervention development, we conducted
a validation using the Theoretical Domains Framework
(see Additional file 4) which reassuringly demonstrated
similar associations between our qualitative data, and our
chosen intervention functions and behavioural change
techniques.
Implications for future research
We used the BCW as a lens for viewing GP behaviour,
understanding what needed to shift and determining
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how this shift could be achieved. Our experience con-
firms the usefulness and generalizability of this ap-
proach. Multimorbidity presents many challenges to
GPs, particularly relating to the conflicts between
patient-centred and disease-focused care but the BCW
approach was not hampered by these complexities.
Based on our experience, the method is potentially ap-
plicable to intervention developers across disciplines as
long as sufficient contextual and empirical data exists or
can be generated.
Throughout this study, we adhered to the ‘less is more’
maxim of intervention design [14]. We could have taken
a more complex multi-faceted approach, such as incorp-
orating other stakeholders, i.e. pharmacists or specialists.
Instead, we adopted the recommendations from the sys-
tematic review by Smith et al. that changes targeting
specific problems are more likely to be effective [8].
Smaller changes can be achieved, sustained and built
upon in future interventions, and substantial behavioural
change is more likely to result from the aggregation of
these smaller changes [14]. We applied the same tenets
to our assessment of outcomes—rather than initially
looking at downstream effects such as changes in pre-
scribing, we will concentrate first on proximal changes
such as implementation of the intervention. Once we
are assured that it is acceptable, feasible and leads to be-
havioural change, we can assess outcomes in prescribing
safety and polypharmacy at a later stage.
To date, there is limited evidence available on which
behavioural change techniques are most effective in spe-
cific settings. We expect that characterising the active
components in the MY COMRADE intervention using
the taxonomy of behavioural change techniques [15] will
aid implementation and replication of the intervention.
The clear specification of the intervention will also facili-
tate a thorough evaluation of the impact of the selected
behavioural change techniques and will help to inform
evidence-based strategies for intervention development
in the future.
In this study, we did not undertake the sixth step
of the BCW relating to policy options in detail. How-
ever, if the intervention is shown to be effective in
our ongoing feasibility and pilot work, scaling-up of
the intervention will require greater consideration of
the external context of healthcare policy and wide-
spread implementation.
Conclusion
This paper describes the development of an intervention
to improve medication management in multimorbidity by
GPs. The intervention, which is called MY COMRADE, is
based on purposively collected data on behaviour in
context and a novel approach to intervention design, the
Behaviour Change Wheel. While the Behaviour Change
Wheel is not a magic bullet for intervention design, this
paper confirms the usability and usefulness of this ap-
proach in a complex area of clinical care. The systematic,
transparent approach used in the development of the MY
COMRADE intervention will facilitate a thorough evalu-
ation of its effectiveness in the next phase of this work.
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